- Home
- ANAB vs PDM Comparison
ANAB vs PDM Comparison
Compare ANAB & PDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANAB | PDM |
|---|---|---|
| Founded | 2005 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Building operators |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2015 | 1997 |
Fundamental Metrics
Financial Performance| Metric | ANAB | PDM |
|---|---|---|
| Price | $48.44 | $9.70 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 4 |
| Target Price | ★ $87.25 | $10.75 |
| AVG Volume (30 Days) | 510.1K | ★ 1.3M |
| Earning Date | 11-03-2026 | 10-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $234,603,000.00 | ★ $564,994,000.00 |
| Revenue This Year | $17.97 | $3.29 |
| Revenue Next Year | $36.88 | $2.41 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 157.01 | N/A |
| 52 Week Low | $30.27 | $6.32 |
| 52 Week High | $73.30 | $10.13 |
Technical Indicators
Market Signals| Indicator | ANAB | PDM |
|---|---|---|
| Relative Strength Index (RSI) | 48.05 | 63.49 |
| Support Level | $44.43 | $9.28 |
| Resistance Level | $51.27 | $9.97 |
| Average True Range (ATR) | 2.29 | 0.23 |
| MACD | 0.44 | 0.09 |
| Stochastic Oscillator | 58.84 | 97.85 |
Price Performance
Historical ComparisonAbout ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About PDM Piedmont Office Realty Trust Inc.
Piedmont Realty Trust Inc is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of 16 MM SF of Class A properties across U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into Piedmont PLACEs that enhance each client's workplace experience.